(Long Island, NY) Bladder outlet obstruction is a condition in which the bladder neck becomes obstructed as a result of an abnormality. This prevents the bladder neck from completely opening during urination. Bladder outlet obstruction is common among men over the age of 50. However, the condition can occur among men of any age, as well as women.

There are a number of signs and symptoms that may indicate bladder outlet obstruction. Men and women who suffer from bladder neck obstruction experience similar symptoms. The signs and symptoms of bladder outlet obstruction may include intermittent urine stream, delayed urine stream, incomplete bladder emptying, incontinence, increased urgency and frequency of urination, and pelvic pain (this symptom is more common in men than women).

The possible causes of bladder outlet obstruction might include:

• Benign prostatic hyperplasia (BPH), which is also known as enlarged prostate. This is the most common cause of bladder outlet obstruction in men.
• Bladder stones
• Prostate cancer
• Scarring of the urinary channel (urethra) or bladder neck, as a result of injury or surgery
• Use of certain medications, including antihistamines, decongestants or drugs to treat overactive bladder

A recent study suggests that the thickness of the bladder wall may predict the severity of bladder outlet obstruction in men. The study included 236 men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. It was conducted by Özer Güzel, MD, and colleagues at the Ankara Numune Research and Training Hospital in Turkey. They examined the relationship between bladder wall thickness and poor indictors for bladder outlet obstruction: International Prostate Symptom Score above 19, Qmax less than 15 mL/min, and post-void residual greater than 100 mL. The investigators used suprapubic ultrasonography to measure bladder wall thickness.

The results showed that the patients had a mean age of 62.5 years and mean bladder wall thickness of 3.8 mm. The mean IPSS, Qmax, PVR, and duration of LUTS were 17.7, 13.7 mL/min, 89.9 mL, and 46.5 months, respectively. These findings showed that bladder wall thicknessincreased when the number of bladder outlet obstruction parameters increased. Bladder wall thickness was 2.9 mm in patients without bladder outlet obstruction, whereas bladder wall thickness was 3.5, 4.1, and 4.5 mm in patients with any 1, any 2, and all parameters of bladder outlet obstruction, respectively.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) Did you know that the number of younger men diagnosed with prostate cancer has increased nearly six-fold in the last twenty years? Today, over 10 percent of new prostate cancer diagnoses in the US occur in young men younger than 55 years old.What’s more alarming is that for younger men, the disease is often much more aggressive. Prostate cancer typically affects men in their 60s, 70s and older, and is often slow-growing. For this reason, older men are likely to die of causes other than prostate cancer, rather than of prostate cancer. But when younger men are diagnosed with prostate cancer, it is likely because they have developed a tumor that is growing quickly and aggressively.

Prostate cancer is the second most common cancer among men in the United States. Itmainly occurs in older men. The average age of diagnosis is about 66, and about six in ten prostate cancer cases are diagnosed in men age 65 or older, according to the American Cancer Society. It is the second leading cause of cancer death in American men; about 1 in 38 will die from it. But what many people are unaware of is that prostate cancer is not just an older man’s disease. Men younger than 50 (as young as 40, and sometimes younger) can get prostate cancer too.

Because of the current PSA guidelines established by governmental agencies like the US Preventive Services Task Force, many doctors or urologists do not recommend PSA tests until a man is in his 50s. In fact, the USPSTF recommends against PSA screening completely, claiming there is not enough evidence to support the benefits of the test. Other agencies or organizations recommend that men begin testing their PSA at age 50 or 55. However, this is simply not good enough.

What men should know:

1. Get a baseline PSA test starting at age 40. Men should have a baseline PSA test starting at age 40. There is no harm in knowing your numbers. PSA results should be discussed with an experienced specialist who can guide you in the right direction about how to follow up and what to be aware of.
2. Know your family’s medical history for prostate cancer. Knowing your family’s medical history is just as important. Men who have a brother or father with a history of prostate cancer are twice as likely to be diagnosed with the disease. For younger men, the risk is even higher if they have multiple relatives with a history of prostate cancer. This should also be discussed with the same experienced specialist who checks your PSA level.
3. African-American men have the highest risk for prostate cancer. African-American men should especially be aware of prostate cancer. African-American men are 60 percent more likely to develop prostate cancer and are 2.5 times more likely to die from it. African-American men are also diagnosed at a younger age (about 3 years younger) and are more likely to have high-grade or aggressive tumors.

Prostate cancer can truly be a “silent killer.” There are usually no symptoms present until the disease is in an advanced stage. This is why early detection is key. Screening for prostate cancer is essential in order to find the disease early. Detecting prostate cancer early allows men to have more treatment options and more effective treatment in general. When prostate cancer is discovered in the early stages when it is still confined to the prostate gland, the cure rate is almost 100 percent. Early detection methods include a PSA (prostate-specific antigen) blood test, digital rectal exam (DRE), a prostate biopsy, and a PCA3 urine test.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) Have you ever wondered what goes on during an orgasm for your man? Is the “big O” entirely different for him, or is that all just a myth?  Although physically similar in that both sexes experience warm, tingly, physical sensations throughout the body, according to science orgasms for men and women differ greatly.

Men are more likely to reach orgasm during sex.  Compared to women, this increased rate of orgasm is due to the fact that a man’s orgasm is driven by stimulation, while the rate of orgasm for a woman is driven by social and environmental factors. Usually thought of as one, orgasm and ejaculation are actually two separate events.  Typically both event happen together, but they don’t need to.  A man may have an orgasm without ejaculation.  Female ejaculation on the other hand is still being demystified by research.

Orgasmic sensation tends to be more localized for men.  The pleasurable contractions involve the PC muscles (by the pubic bone), anal sphincter, rectum, perineum and genitals. Even though orgasms vary in type and strength from woman to woman – compared to men, women’s orgasm tends to be more of a full-body experience.

LENGTH

Men typically have much shorter orgasms than women.  On average a woman’s orgasm lasts a whopping 14 seconds longer than a man’s.

RECOVERY TIME

Men have a much longer refractory period, or recovery phase, (one hour – one day) that is needed between orgasms.  Women on the other hand tend to have a shorter refractory period, which leads us to our next topic.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) It’s easy to laugh at poor George Costanza for his shrunken manhood, but some reports suggest that only about 55% of men are satisfied with their penis size. Some men actually seek potentially dangerous surgical solutions to a problem that is often only in their head. Clearly men have a much distorted picture of what the average size is or what the best size is for optimal sexual performance. A number of studies have tried to understand this cultural connotation with penis size and sexual performance.

EXAMINING MALE PRIVATE PARTS

A significant study from the UK analyzed 96 previous papers on this very top-of-mind male part. They excluded most papers that analyzed erectile dysfunction. For meta-analysis, this left 20 studies, each conducted to gauge a man’s height and the circumference of his penis. The total private parts analyzed in these studies were over 15,000. The study showed that an average erect circumference is 4.5 inches, the researchers found.

The study’s lead author said the goal was to construct graphical representations of penis measurements, spanning many different ages and races. Putting it in a graph-form emphasizes the average size of most penises.

“Men may present to urologists or sexual medicine clinics with a concern with their penis size, despite their size falling within a normal range. This type of concern is commonly known as ‘small penis anxiety’ or ‘small penis syndrome,'” said Dr. David Veale, the study’s lead author.

These nomograms (graphs) may help urologists counsel men with this issue and also understand the correlation between penis size and issues like condom failure and penile dimensions.

WHO CARES ABOUT SIZE?

The authors also concluded that past research has shown 85 percent of women were satisfied with their partner’s penis size, but only 55 percent of the men were satisfied with their own size.

MEN’S ANXIETY AROUND SIZE

Many men experience performance anxiety around their penis size. There are many psychological factors that play a role in issues like erectile dysfunction and premature ejaculation. This study may help men understand the widespread average among others and help them mentally cope with their particular size.

Unfounded worries about inadequacy in penis size are not helped by the fact that a man’s own view of his penis automatically makes it look smaller to him than to someone else. This is simply because looking down at the penis from above makes it appear smaller, compared with how it looks straight on, or from the side.

Penile Prosthesis is a common procedure men can have if they have issues of erectile dysfunction. A penile prosthesis is another treatment option for men with erectile dysfunction. These devices are either malleable (bendable) or inflatable. The simplest type of prosthesis consists of a pair of malleable rods surgically implanted within the erection chambers of the penis. With this type of implant the penis is always semi-rigid and merely needs to be lifted or adjusted into the erect position to initiate sex. Today, many men choose a hydraulic, inflatable prosthesis, which allows a man to have an erection whenever he chooses and is much easier to conceal. It is also more natural.

Even though this procedure is quite safe and effective, men who experience real issues with erectile dysfunction should consult a urologist. Believing your penile dimensions are too small is not a valid enough reason to pursue a procedure of this nature.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) The PHI test is a new blood test that may eventually replace the PSA test when testing for prostate cancer. It is a simple, noninvasive blood test that is three times more specific than PSA in detecting prostate cancer. Controversy remains surrounding the use of the PSA test to screen for prostate cancer. This is due to the belief that the PSA test may lead to over-diagnosis and over-treatment in men with low-grade, less aggressive forms of the disease.

The Prostate Health Index (phi) test, now available nationwide (although New York state is still currently awaiting licensing for this test) through Innovative Diagnostics Laboratory, could fill the diagnostic gap clinicians currently have when screening for prostate cancer.  By using three different prostate specific markers, the test three times more specific for prostate cancer than the current PSA test.  Over the last several years, there has been much debate in the realm of over-screening, over-diagnosis, and the inaccuracy of diagnostic tools in prostate cancer.  This test greatly improves this dilemma by giving clinicians more accurate information on what an elevated PSA level might mean and the probability of finding cancer on biopsy. This improvement will allow a decrease in the number of prostate biopsies that are negative for cancer and done unnecessarily each year.

The PSA test is also not specific to prostate cancer and as a result, many men often have unnecessary biopsies. Prostate cancer diagnoses are on the rise, and the disease remains the second most common cancer in American men as well as the second leading cause of cancer deaths.

Below are a few other factors which will also affect PSA levels:

1. Prostate Biopsy or prostate massage: either will increase PSA levels temporarily
2. Race: African-Americans have higher baseline PSA levels than whites
3. Prostate volume: Increase in PSA level of 4% for every ml of prostate volume
4. Age: Older men have higher baseline PSA
5. 5-alpha reductase inhibitors (Finasteride and Dutasteride): This class of drugs is used in treating BPH and male pattern baldness. Will decrease PSA by 50% after 6 months of therapy

Because the PSA test is not specific for prostate cancer, there are several other possibilities as to why your it may be elevated including an enlarged prostate, prostatitis, inflammation, or an urinary tract infection. But when the PSA is above 4.0 ng/ml, or is “abnormal”, and other possible causes have been ruled out, the next step for the patient is to have a prostate biopsy. If prostate biopsy is negative, but the PSA is still high, the patient usually has to have a repeat biopsy every six months or year.

There are about 1.5 million prostate biopsies each year and about 25 million men have had at least one negative biopsy. The PHI test improves the diagnosis of prostate cancer by using three different prostate specific markers, which makes the test three times more specific for prostate cancer compared to the current PSA test. The test gives doctors a more accurate picture in regards to what an elevated PSA level indicates as well as the probability of finding cancer on a prostate biopsy.

The PHI test measures total PSA as well as two special forms of the protein: free PSA (fPSA), and pro2PSA. tPSA includes all types of PSA circulating in the bloodstream, whether free or bound to other proteins; fPSA is PSA that circulates as a free protein, unattached to any other proteins; and pro2PSA is a form of PSA that is highly expressed in prostate cancer tissue and is associated with more aggressive disease. Using these three values, a PHI score is calculated. The PHI score provides a more accurate measurement to assess prostate cancer risk than any known PSA-based marker alone. And by using pro2PSA, the PHI test can detect more aggressive cancers. This reduces the harm many men experience with overtreatment.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) What is Cyberknife? Cyberknife is a form of stereotactic body radiation therapy (SBRT) and robotic-assisted radiosurgery (not actual surgery) that utilizes a computerized robot to automatically deliver high doses of radiation to the prostate gland. Fiducials are implanted into the body so that the Cyberknife machine can adjust to movement during each treatment.

Who is Cyberknife recommended for? Cyberknife is recommended for men with cancer limited to the prostate, and men with low to moderate risk prostate cancer.

Pros vs. Cons: The pros of Cyberknife include no hospitalization, low levels of toxicity produced, and less pain compared to other procedures. The cons of Cyberknife include fatigue, erectile dysfunction (20 to 30 percent of patients develop erectile dysfunction), there is no doctor or surgeon controlling the device, a lack of high definition internal visuals to accurately diagnose and treat prostate cancer, it can be difficult to accurately stage the cancer, it requires multiple trips to the hospital for treatments, and it is a fairly new surgery which means there is limited clinical history to determine the true long-term effectiveness.

What is robotic surgery for prostate cancer? Robotic surgery for prostate cancer is also known as Da Vinci Robotic Prostatectomy or Robotic-Assisted Laparoscopic Radical Prostatectomy (RALRP). Da Vinci Robotic Prostatectomy is a surgical procedure performed by a surgeon (and his/her team) with the aid of computer-enhanced robotic system. State-of-the-art technology and tools are 100 percent in the control of the surgeon, which allows him or her to see a magnified, high-resolution view of the operating field to safely and efficiently remove the cancerous prostate.

Who is robotic prostate surgery recommended for? Robotic prostate surgery is recommended for men healthy enough for surgery and men with prostate cancer that has been isolated the prostate.

Pros vs. Cons: The pros of robotic prostate surgery include high rates of curing cancer, accurate staging of the cancer, minimal blood loss, less pain, shorter recovery times, shorter hospital stays (1 to 2 days), extreme accuracy and precision of necessary surgical instruments, high definition magnified visibility of the prostate and surrounding tissues and organs, high rate of normal sexual function after surgery when performed by a skilled and experienced robotic surgeon, and the prostate cancer is completely removed resulting in higher cancer cure rates when performed by a skilled and experienced robotic surgeon. The cons of robotic prostate surgery include possible erectile and urinary side effects after surgery when the procedure is performed by a less-skilled and inexperienced surgeon.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) A new genetic test has recently become available called Oncotype DX. The test is made by Genomic Health and will now be available at Dr. Samadi’s Prostate Cancer Center in New York City. What is Oncotype DX? The Oncotype DX prostate cancer test is a biopsy-based genetic test that can be combined with other measures to predict the aggressiveness of prostate cancer. The test applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions for each individual patient.

The Oncotype DX prostate cancer test works by analyzing the genes in your tumor and predicting the aggressiveness and biological makeup of your prostate cancer. This is an advantage because neither of these things can be done otherwise without a pathological analysis of the prostate tissue which can only be done when the prostate is actually removed surgically. The Oncotype DX test allows for this analysis without having to remove the prostate.

The test is a multi-gene RT-PCR expression analysis developed to work in combination with prostate needle biopsies. It measures the expression of 12 cancer-related genes representing four biological pathways and 5 reference genes, which are then combined to calculate the Genomic Prostate Score (GPX). This biopsy-based score has been clinically validated as a predictor of aggressive prostate cancer.

The Oncotype DX test examines certain genes in a sample of your tumor taken which is collected during a prostate biopsy. This allows the urologist to understand how those genes are interacting with one another and functioning. Determining the activity of the genes and how they influence and regulate the behavior of the prostate tumor allows for a deeper understanding in regards to how likely it is that your prostate cancer will grow and spread. The information that Oncotype DX provides for prostate cancer patients can help by allowing the patient and their doctor to determine the most optimal treatment plan specifically for that patient and their cancer.

For men with an elevated PSA, high-risk for prostate cancer or who’ve had a previous biopsy, Oncotype DX may be the next step in assessing the potential growth rate of the tumor or how aggressive the cancer currently is. This directly leads to which treatment option is right for the patient. This genetic test gives us the ability to treat each patient individually.

Three studies presented at the 110th Annual Scientific Meeting of the American Urological Association this year showed this test improved patient risk assessment for high and low-risk prostate cancers and even reduced cost of overall prostate cancer care. The Oncotype DX Genomic Prostate Score (GPS) has also shown promise in helping to further examine the biology and development of prostate cancer in African American men who are at a high risk for the disease.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) Prostate cancer is the second most common cancer among men in the United States. African-Americans have the highest risk of developing prostate cancer among any other racial group. Prostate cancer in African-American men also tends to be more aggressive.

Key statistics about African-American men and prostate cancer:

• African American men are twice as likely to develop prostate cancer compared with Caucasian men and are nearly 2.4 times as likely to die from the disease.
• About 19 percent, or nearly one in five, African-American men will be diagnosed with prostate cancer, and five percent of those will die from this disease.
• Prostate cancer is the fourth most common reason overall for death in African-American men.
• The risk of an African-American man developing prostate cancerincreases significantly if there is a family history of prostate cancer.
• African-American men with an immediate family member who had prostate cancer have a one in three chance of developing the disease. Their risk increases to 83 percent with two immediate family members having the disease, and then increases to 97 percent if they have three immediate family members who developed prostate cancer.
• The American Cancer Society recommends that African-American men discuss testing for prostate cancer with their doctor at age 45, or at age 40 if they have close relatives who have had prostate cancer before age 65.

A new study suggests that African-American men may produce less PSA compared to Caucasian men with low-risk prostate cancer. While more research is needed to confirm these findings, it is possible that the confirmed findings could change the way African-American men with prostate cancer are monitored via active surveillance. The study was published in the Journal of Urology.

The study was conducted atthe University of Miami Miller School of Medicine by Oleksandr N. Kryvenko, MD and hiscolleagues. The study involved 66 African-American men and 348 Caucasian men who all had a Gleason Score 3+3. The researchers measured tumor volume in radical prostatectomy specimens and then compared the patients’ PSA, PSA density, PSA mass, as well as clinical and pathologic parameters.

The results showed that while the African-American men had heavier prostate glands, theyhad the same PSA mass as the Caucasian men with the same tumor volumes. In other words, the PSAD was significantly lower in African Americans. They also found that it was the benign prostate tissue that was contributing less PSA rather than the tumor.

According to the researchers, “This finding has practical implications for active surveillance criteria in African-American men. If benign tissue in African-American men produces less PSA, then the PSAD will be lower compared to Caucasians even when cancer volumes are the same between the 2 groups.”

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.

(Long Island, NY) Cryotherapy utilizes extreme cold temperatures of -40 degrees celsius to freeze and eliminate cancerous tissue within the prostate gland. Cryotherapy is performed by the insertion of a thin metal needle or probe inserted directly into the prostate gland. To facilitate this insertion a small incision is made between the anus and scrotum. Additional care is given to protect the urethra from the colder temperatures by administering a flow of warm saline through a catheter. The surgeon performing the procedure will also use visual data taken by ultrasound for use as a visual reference guide. By utilizing the ultrasound images the surgeon can easily identify the cancerous tissue thereby any potential damage to healthy prostate tissue. Many experts believe that Cryotherapy has the potential to effectively treat recurrent prostate cancer in cases where traditional methods such as Radiation Therapy have failed.

How it’s done

The surgeon will insert the needle directly into the prostate gland and infuse it with a freezing liquid suchas nitrogen or argon gas. Heat is then drawn from the prostate gland and as a result of the extracted heat a swell of ice crystals or “ice balls” to form. This then causes the cell membranes to rupture causing cellular damage and finally destroying the cancerous cells. Afterwards white blood cells will take care of any dead cells or tissue remaining in the prostate gland.

Advantages to Cryotherapy

Several studies on Cryotherapy as a treatment for prostate cancer highlight many of the advantages it has over surgery and radiation therapy. Some of those advantages seem to be prevalent amongst patients with early stage prostate cancer. Advantages for choosing Cryotherapy include:

• Less invasive than many procedures
• Short recovery time
• Reduced blood loss
• Favorable success rate

Side Effects

As with any type of treatment for prostate cancer there is always the potential for side effects. While the studies on Cryotherapy have shown its promise many experts feel that it effectiveness in eliminating prostate cancer stills requires further study. Some of these side effects include:

• Urinary Incontinence
• Erectile Dysfunction
• Infection
• Blood in urine
• Swelling of the penis and scrotum
• Obstruction of the urethra
• Injury to the urethra or bladder

Although instances are rare there is also a chance that Cryotherapy can damage other tissue and organs near the prostate gland. Discuss all of your options with your doctor before deciding to proceed with Cryotherapy. Even if Cryotherapy fails in eliminating a patient’s prostate cancer it can still be followed by other standard treatments such as Radiation Therapy.

Dr. Samadi is a board-certified urologic oncologist trained in open and traditional and laparoscopic surgery, and an expert in robotic prostate surgery. He is chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. He is a medical correspondent for the Fox News Channel’s Medical A-Team and the chief medical correspondent for am970 in New York City, where he is heard Sundays at 10 a.m.

Learn more at roboticoncology.com and SamadiMD.com. Follow Dr. Samadi on Twitter and Facebook.